Skip to main content

“I am a Canadian, free to speak without fear, free to worship in my own way, free to stand for what I think right, free to oppose what I believe wrong, or free to choose those who shall govern my country. This heritage of freedom I pledge to uphold for myself and all mankind.” ~~ John G. Diefenbaker

FRASER INSTITUTE -- Canada’s comparatively weak intellectual property protections limit access to life-saving drugs


Because Canada’s protection of intellectual property in the life sciences—including biology and biochemistry—lags behind other industrialized countries, Canadian patient access to potentially life-saving biologic medicines is comparatively limited, finds a new study released today by the Fraser Institute, an independent, non-partisan Canadian public policy think-tank.

 

Cutting-edge biologic drugs are treating previously untreatable conditions, often with fewer adverse effects, improving the health of patients and saving lives worldwide,” said Kristina Acri, associate professor of economics at Colorado College, senior fellow at the Fraser Institute and author of Biologics and Biosimilars: A Primer.

 

According to the study, as of December 2018 (the latest month of comparable data), Canada has approved only 10 “biosimilars,” which are versions of biologic drugs, compared to 15 in the United States, 20 in Australia and 62 in the European Union.

 

Biologic drugs are produced from (or contain elements of) living organisms. They are more complicated—and more expensive—to develop, produce, distribute and dispense than other medicines.

 

Subsequently, the ability of drug companies to protect their intellectual property—for example, through data exclusivity, which essentially prevents competing firms from producing generic versions of the drugs for a period of time—is essential for incentivizing the development of biologics, particularly because biopharmaceutical innovations are easily copied and sold by competitors.

 

Unfortunately, Canada’s current intellectual property laws are weak compared to laws in other jurisdictions including the U.S. and EU. For example, Canada has one of the shortest terms of data exclusivity for pre-clinical and clinical trials.

 

If Canadian policymakers want to improve access to state-of-the-art drugs in Canada, they must strengthen protections for intellectual property,” Acri said.

Comments

Popular posts from this blog

NDP Government Blames Everyone but Themselves

The federal government has announced new measures to support British Columbia's forestry sector, including $65 million in funding for projects across the province. While any support is welcome, it falls far short of the level of assistance other provinces have secured for key industries. Conservative Forests Critic Ward Stamer says the NDP government needs to take responsibility for its mismanagement of B.C.’s forest industry instead of trying to pass on the blame. Despite promising to create more jobs in the forest sector, the NDP government has overseen the loss of thousands of forestry jobs and 21 mill closures which have devastated communities. “If Premier Eby spent more time addressing the regulatory issues impacting the forestry sector than he did complaining about the federal government, we would not be in the position we are now,” said Stamer. “And instead of trying to place the blame for mill closures on Donald Trump, Minister of Forests Ravi Parmar should t...

Tourists Rack Up $200M in Unpaid Health Bills While BC Patients Wait Years for Care

While British Columbians wait years for basic medical care, the NDP government has allowed non-residents to rack up $200.6 million in unpaid health bills since 2020-2021. New research from SecondStreet.org, obtained through a freedom of information request, revealed that people from outside Canada are coming to BC, receiving health services, and leaving without paying their bills.  The losses span every health region in the province. "British Columbians are not guaranteed timely access to healthcare, be it treatment or diagnostics, and this situation continues to deteriorate under the NDP," said Anna Kindy, MLA for North Island and Critic for Health. "Taxpayers are footing the bill for tourists' health treatments to the tune of over $200 million, enough to cover over 21,000 hip replacements in this province while British Columbians wait months to years for that surgery.” The research found BC has the worst record of any province in Canada examined so far. Under a dec...

NDP Finance Minister Given "F" on Report Card by Canadian Taxpayers Federation

Peter Milobar, MLA for Kamloops Centres and Official Opposition Finance Critic, released the following statement in response to the Canadian Taxpayers Federation's 2026 Finance Minister Report Card, which ranked BC Finance Minister Brenda Bailey dead last among provincial finance ministers in Canada with an overall grade of "F":  "British Columbians didn't need a report card to know things are headed in the wrong direction. They see it every time they pay their bills, try to buy a home, or watch another government deficit pile up. But now an independent national organization has confirmed that NDP Brenda Bailey is the worst-rated finance minister in Canada. "After nearly a decade of decline under this NDP government, British Columbia has become a province where people pay more, government borrows more, and families get less in return. We have some of the highest debt in the country, repeated credit downgrades, and no credible plan to get our finances back on...

Labels

Show more